Moderna Stock Q4 Earnings Preview: RSV mRNA Vaccine Scrutiny, Diminishing Spikevax Revenue, FDA Approval In Focus
Portfolio Pulse from Surbhi Jain
Moderna Inc (NASDAQ:MRNA) is set to report its Q4 earnings on Feb. 22, with expectations of a negative 99 cents EPS and $2.53 billion in revenues. The focus is on the scrutiny of its RSV mRNA vaccine, diminishing Spikevax revenue, and the potential FDA approval in 2024. Moderna's stock has declined 83% from pandemic highs due to these challenges. Analysts maintain a Buy rating with a target of $154.44, despite recent setbacks and competition from GSK (NYSE:GSK) and Pfizer Inc (NYSE:PFE).
February 21, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
GSK competes with Moderna in the RSV vaccine market, posing a challenge to Moderna's mRNA vaccine pipeline.
GSK's position as a competitor in the RSV vaccine market introduces additional pressure on Moderna, but the direct short-term impact on GSK's stock is neutral, pending Moderna's earnings outcomes and market responses.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Moderna faces critical Q4 earnings amidst RSV vaccine scrutiny and declining Spikevax revenue. Analysts remain positive with a Buy rating and a $154.44 price target.
Moderna's Q4 earnings are pivotal due to the RSV vaccine scrutiny and Spikevax revenue concerns. However, analysts' continued support with a Buy rating and a significant price target suggests a balanced short-term impact, with potential for recovery if Moderna addresses these challenges effectively.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100
NEUTRAL IMPACT
Pfizer Inc (PFE) is a competitor to Moderna in the RSV vaccine market, which could influence the competitive dynamics.
As a competitor in the RSV vaccine market, Pfizer's position could be influenced by Moderna's performance and strategic decisions. However, the immediate impact on Pfizer's stock is neutral, awaiting further developments.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50